{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T16:27:20Z","timestamp":1788884840678,"version":"build-2803163510"},"reference-count":23,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The use of cisplatin is limited by the development of nephrotoxicity, with an incidence approaching 30%. It is unclear if a risk prediction score can effectively predict the development of nephrotoxicity throughout all cycles of cisplatin therapy among outpatients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Retrospective, observational study evaluating adult patients receiving cisplatin in outpatient infusion centers from January 2009 to November 2019 (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a0186). A risk prediction score consisting of patient age, cisplatin dose, hypertension, and serum albumin was calculated to predict the risk of cisplatin\u2010induced nephrotoxicity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The incidence of nephrotoxicity was 23.7% overall, with 8.1% of patients developing cisplatin\u2010induced nephrotoxicity after the first dose. Patients who developed nephrotoxicity had a higher mean risk prediction score compared to patients who did not have nephrotoxicity (4.0\u00a0\u00b1\u00a02.0 versus 2.9\u00a0\u00b1\u00a02.1,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.004, respectively). Multivariate logistic regression demonstrated each 1\u2010point increase in the risk prediction score increased the odds of nephrotoxicity by 26.5% (OR: 1.27; 95% CI: 1.02\u20131.57,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.034). Presence of diabetes mellitus increased the odds of cisplatin\u2010induced nephrotoxicity (OR 3.66; 95% CI: 1.43\u20139.33,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.007), whereas receipt of greater than or equal to 1 liter of 0.9% sodium chloride was protective, decreasing the odds of developing nephrotoxicity by 25%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>By identifying patients at the highest risk of cisplatin\u2010induced nephrotoxicity, providers can individualize risk reduction strategies. The use of a risk prediction model successfully predicted the risk of nephrotoxicity throughout all cycles of cisplatin in an outpatient setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/phar.2500","type":"journal-article","created":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T18:26:55Z","timestamp":1610562415000},"page":"184-190","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Cisplatin\u2010induced nephrotoxicity in an outpatient setting"],"prefix":"10.1002","volume":"41","author":[{"given":"Carly V.","family":"Burns","sequence":"first","affiliation":[{"name":"Department of Pharmacy Ascension St. John Hospital Detroit MI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8175-372X","authenticated-orcid":false,"given":"Stephanie B.","family":"Edwin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Ascension St. John Hospital Detroit MI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Szpunar","sequence":"additional","affiliation":[{"name":"Department of Medical Education Ascension St. John Hospital Detroit MI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Forman","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Ascension St. John Hospital Detroit MI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,2,17]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-017-0392-z"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.13005\/bpj\/1608"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(89)90006-0"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00306754"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5002786"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1Q333"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155216656927"},{"key":"e_1_2_7_9_1","volume-title":"Cisplatin [package insert]","year":"2015"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-016-1327-z"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.7161"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0319"},{"key":"e_1_2_7_13_1","unstructured":"National Comprehensive Cancer Network.NCCN clinical practice guidelines in oncology.https:\/\/www.nccn.org\/professionals\/physician_gls\/default.aspx. Accessed September 20 2019."},{"issue":"1","key":"e_1_2_7_14_1","first-page":"31","article-title":"Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: a southwest oncology group study","volume":"66","author":"Al\u2010Sarraf M","year":"1982","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-012-0821-7"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12781"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"e_1_2_7_18_1","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE).Cancer Therapy Evaluation Program (CTEP).https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_40. Accessed October 1 2019."},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyt128"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-003-0620-1"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/1120009X.2020.1713507"},{"issue":"4","key":"e_1_2_7_22_1","first-page":"263","article-title":"Effect of short hydration on cisplatin\u2010induced nephrotoxicity in cancer patients: a retrospective study","volume":"11","author":"Ashrafi F","year":"2017","journal-title":"Int J Hematol Stem Cell Res"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/28.3.168"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1Q333"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2500","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/phar.2500","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2500","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:43:30Z","timestamp":1761054210000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.2500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1002\/phar.2500"],"URL":"https:\/\/doi.org\/10.1002\/phar.2500","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"2020-09-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}